Application of Iquamycin in Preparation of Osteoclast Differentiation Inhibitor

Abstract

The invention discloses the application of iquamycin in the preparation of osteoclast differentiation inhibitor. The present invention discloses that iklamycin can effectively generate and differentiate osteoclasts, and can produce an inhibitory effect only at a concentration of 0.1 μM, and does not affect cell survival and does not produce cytotoxicity at a concentration of 4 μM or below Therefore, it can effectively replace the existing bisphosphonate drugs and denoximab, reduce the area of ​​bone depressions formed by osteoclasts on bone slices, inhibit the bone resorption activity of osteoclasts, and at the same time down-regulate the expression of NF-κB and NFATc1 expression, has extremely high application value.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, and in particular relates to the application of ikamycin in the preparation of an osteoclast differentiation inhibitor. Background technique [0002] Osteoclasts (OCs) are the only cells in the human body with bone resorption function. Osteoclasts originate from cells of the bone marrow monocyte-macrophage lineage, which are giant multinucleated cells formed by the fusion of mononuclear precursor cells in various ways. The excessive activation of osteoclasts is not only common in menopausal osteoporosis, but also in bone destructive diseases such as bone loss caused by inflammatory diseases (such as bacterial infections), rheumatoid arthritis, and tumor bone metastasis. Therefore, drugs targeting osteoclasts and inhibiting osteoclastogenesis or function can only be an important means of preventing and treating related bone destructive diseases. [0003] At present, the relevant inhibi...

AI Technical Summary

Problems solved by technology

Although these two types of drugs can inhibit the differentiation or function of osteoclasts, they both have serious complications and unbearable side effects for patients

For example, taking bisphosphonates for a long time will inhibit the natural renewal of bone tissue, which will easily cause fractures; while denosimab needs subcutaneous injection, which is expensive. The most important thing is that long-term use of denosimab can cause mandibular necrosis other serious complications

Images